US Cancer Biosimilar Market Opportunity, Drug Dosage, Price and Clinical Trials Insight 2026

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

"US Cancer Biosimilar Market Opportunity, Drug Dosage, Price and Clinical Trials Insight 2026" Report highlights:

US Cancer Biosimilar Market Opportunity: > US$ 15 Billion By 2026
Currently 29 Cancer Biosimilar Approved In US Market
Pricing and Dosage Insight On More Than 10 Cancer Biosimilar Commercially Available In US Market
Cancer Biosimilar In Clinical Trials: > 10 Biosimilars
Comprehensive Insight On Cancer Biosimilar Clinical Trials Insight By Company and Indication
Insight On 15 Potential Cancer Biosimilars Market Opportunity By Popular Drugs Patent Expiry: Erbitux, Vectibix, Yervoy, Trodelvy, Perjeta, Gazyva, Darzlex, Xgeva, Cyramza, Kadcyla, Opdivo, Tagraxofusp, Tecentriq, Keytruda, Imfinzi

The US cancer biosimilar market landscape is inclined towards entering the time of a splendid change. In the past few years, the country has observed a high influx in the number of biosimilar products for the benefit of the patient population, as the price of the branded drugs in the country such as immunotherapy and many more were in rise. Therefore, the arrival of cancer biosimilar drug market in the country has played an important role in contributing a significant share in the overall cancer therapeutics market in the country. It can be observed for US cancer biosimilar market that despite of having tough competition, the market has been able to sustain the growth which is however very critical as millions of patients were highly dependent on the regulatory benefits of the market, thus promoting the entire market towards a very important playing field in the cancer therapeutics market.

From the past few years, the US cancer biosimilar market has continued to observe a focus on the entire transformation of the cancer therapeutics market. The entire transformation caused by the market in the past few years is estimated to be using several technologies such as commercialization and marketing strategic tools and programs that were hardly used for any biologic drug market. It can be estimated for the market that in a short timeframe, has created a novel biotech space, inclining the market and investors towards a strategic important business model in the future years. In addition to this, other driving forces available in the market such as increase in cancer cases and high rate of cancer therapies are likely to accelerate the market towards superior change and drastic arrival of applications for patient use.

Overall market of US cancer biosimilar market is highly driven by the medical progress that is occurring in the country. It can be concluded for the US cancer generics market that the whole market is centric towards cancer patient care. In order to boost the market, government of the country is also promoting the market by forcing on factors such as high influx of local drug makers in the country, increased funds for biosimilar drugs development, aligning the physicians to prescribe biosimilar drugs instead of biologic drugs and many more. Eventually, the market has inclined the entire cancer therapeutics market towards observing less cancer mortality rate and net consumption of the drugs that is high when compared with the market status of biologic drugs for different cancer indications.

As per "US Cancer Biosimilar Market Opportunity, Drug Dosage, Price and Clinical Trials Insight 2026" report findings, it is witnessed that there are several different prominent factors that have led to the successful uptake of the market at regional and global level, other than the prominent drivers. Some of the factors involve: high practice for cancer biosimilar at RandD level, high take of clinicians, physicians, payers, manufacturers and legislators on expanding the market trends and opportunities. In addition, difference in the context of development costs, competition, entrant entry and many more in the US when compared with other markets of the world such as EU are also believed to create a landscape that is advancing faster. The entire country is poised towards spiraling research and development for the market, thus inclining the market towards delivering promising opportunities. It is predicted that the US cancer biosimilar market has helped the oncology researchers to navigate through the utmost need of the patients and deliver a course of change that could help the entire cancer therapeutics market at regional and international level offer multiple opportunities.

Biosimiliars: A New Era in Cancer Therapeutics

1.1 Overview to Cancer Biosimilars

1.2 History of Biosimilars

Development of Biosimilars

Need of Cancer Biosimilars in US

US Comparative Price Analysis of Marketed Cancer Bosimilars

4.1 Avastin

4.2 Herceptin

4.3 Rituximab

US Reimbursement Scenario for Cancer Biosimilars

5.1 Current Scenario

5.2 Future Potential of Reimbursement Scenario

US Cancer Biosimilar Market Overview

6.1 Current Biosimilar Market Scenario

6.2 US Cancer Biosimilar Market

6.3 Off Going Patents: Biosimilar Opportunity Ahead

US Cancer Biosimilar Market by Product

7.1 Rituximab

7.2 Herceptin

7.3 Avastin

US Potential Cancer Biosimilars Market Oppotunity By Popular Drugs Patent Expiry

8.1 Erbitux Biosimilar

8.2 Vectibix Biosimilar

8.3 Yervoy Biosimilar

8.4 Trodelvy Biosimilar

8.5 Perjeta Biosimilar

8.6 Gazyva Biosimilar

8.7 Darzlex Biosimilar

8.8 Xgeva Biosimilar

8.9 Cyramza Biosimilar

8.10 Kadcyla Biosimilar

8.11 Opdivo Biosimilar

8.12 Tagraxofusp Biosimilar

8.13 Tecentriq Biosimilar

8.14 Keytruda Biosimilar

8.15 Imfinzi Biosimilar

US Biosimilar Clinical Pipeline By Company Indication and Phase

9.1 Preclinical

9.2 Phase-I

9.3 Phase-III

9.4 Preregistration

9.5 Registered

US Marketed Biosimilar Clinical Insight

US Cancer Biosimilar Market vs. Global Cancer Biosimilar Market

11.1 Europe Cancer Biosimilar Market

11.2 Japan Cancer Biosimilar Market

11.3 India Cancer Biosimilar Market

11.4 China Cancer Biosimilar Market

11.5 South Korea Cancer Biosimilar Market

US Biosimilar vs Generic Cancer Drug Market

US Cancer Biosimilar Market Dynamics

13.1 US Cancer Biosimilar Market Drivers

13.2 Barriers to US Biosimilar Market

US Cancer Biosimilar Future Outlook

Competitive Landscape

15.1 Amgen

15.2 AstraZencea

15.3 Biogen

15.4 Coherus Bioscience

15.5 Eli Lilly

15.6 F. Hoffmann-La Roche and Co.

15.7 Merck

15.8 Mylan Pharmaceuticals

15.9 Pfizer

15.10 Teva Pharmaceutical

Figure 1-1: List of Approved Cancer Biosimilars in US

Figure 2-1: Development Pathway for Biosimilar vs. Traditional

Figure 2-2: Development Process for Biosimilars

Figure 3-1: US – Spending on Cancer Care (US$ Billion), 2015-2030

Figure 4-1: Biosimilar Market Relationship

Figure 4-2: US – Avastin, Mvasi and Zirabev Approval Year

Figure 4-3: Avastin – Cost of Supply of 4ml, 16ml, 40ml and 160ml Intravenous Solution (US$), February’2021

Figure 4-4: Mvasi – Cost of Supply of 4ml and 16ml Intravenous Solution (US$), February’2021

Figure 4-5: Zirabev – Cost of Supply of 4ml and 16ml Intravenous Solution (US$), February’2021

Figure 4-6: US - Average per Unit Cost of Avastin, Mvasi and Zirabev (US$), February’2021

Figure 4-7: US – Herceptin and its Biosimilar Approval Year

Figure 4-8: Herceptin – Cost of Supply of 10 Powder Injections and per Unit Cost of 150mg Injection (US$), February’2021

Figure 4-9: Ogivri – Cost of Supply of Intravenous Powder of 150mg and 420mg (US$), February’2021

Figure 4-10: Kanjinti – Cost of Supply of Intravenous Powder of 150mg and 420mg (US$), February’2021

Figure 4-11: Herzuma – Cost of Supply of Intravenous Powder of 150mg and 420mg (US$), February’2021

Figure 4-12: Ontruzant – Cost of Supply of Intravenous Powder of 150mg and 420mg (US$), February’2021

Figure 4-13: Average Cost of 150mg Powder of Herceptin and its Biosimilar (US$), February’2021

Figure 4-14: US - Rituximab, Truxima and Ruxience Approval Year

Figure 4-15: Rituximab – Cost of Supply of 10ml, 50ml and 100ml Intravenous Solution (US$), February’2021

Figure 4-16: Truxima - Cost of Supply of 10ml and 50ml Intravenous Solution (US$), February’2021

Figure 4-17: Ruxience - Cost of Supply of 10ml and 50ml Intravenous Solution (US$), February’2021

Figure 4-18: Average Cost of per Unit Supply of Rituximab, Truxima and Ruxience (US$), February’2021

Figure 4-19: Riabni - Cost of Supply of 10mg and 500mg Intravenous Solution (US$)

Figure 5-1: Kanjinti – Annual Treatment Cost and Reimbursement Cost (US$)

Figure 5-2: Kanjinti- In Pocket Cost and Out Pocket Cost (%)

Figure 5-3: Mvasi – Annual Treatment Cost and Reimbursement Cost (US$)

Figure 5-4: Mvasi - In Pocket Cost and Out Pocket Cost (%)

Figure 5-5: Herzuma - Annual Treatment Cost and Reimbursement Cost (US$)

Figure 5-6: Herzuma - In Pocket Cost and Out Pocket Cost (%)

Figure 5-7: US – Cancer Related Healthcare Spending (US$ Billion), 2019-2030

Figure 5-8: US- Cancer Healthcare Spending by Type

Figure 5-9: Total Cost Savings by Biosimilars by Indication (%), 2019

Figure 5-10: US – Total Cancer Spending and Cost Saving by Biosimilars (US$ Billion), 2019

Figure 5-11: US – Total Cancer Spending and Cost Saving by Biosimilars (US$ Billion), 2030

Figure 6-1: US – Biosimilar Market Size (US$ Billion), 2019-2026

Figure 6-2: US – Cancer Incidence and Mortality (Million), 2020 and 2040

Figure 6-3: US – FDA Approved Biosimilars by Indication

Figure 6-4: US – Cancer Biosimilar Share by Product (%), 2020

Figure 6-5: US – Biosimilar Market by Disease Indication, 2020

Figure 6-6: US – Panitumumab FDA Approval and Patent Expiration Year

Figure 6-7: US – Alemtuzumab FDA Approval and Patent Expiration Year

Figure 6-8: US – Yervoy FDA Approval and Patent Expiration Year

Figure 6-9: US – Parjeta FDA Approval and Patent Expiration Year

Figure 6-10: US – Cyramza FDA Approval and Patent Expiration Year

Figure 6-11: US- Patent Approval and Expiration of Biological Cancer Drugs

Figure 7-1: Rituximab Market by Region (%), 2019

Figure 7-2: US – Ruxience Market Size (US$ Million), 2019 and 2020

Figure 7-3: Ruxience – Market Size by Region (%), 2020

Figure 7-4: US – Ruxience Market Size (US$ Million), 2021-2026

Figure 7-5: US – Rituximab Biosimilar Market Size (US$ Billion), 2020-2026

Figure 7-6: US – Rituximab Market by Product (%), 2019

Figure 7-7: US – Expected Rituximab Market by Product (%), 2026

Figure 7-8: Herceptin – Market Size by Region (%), 2019

Figure 7-9: US- Herceptin Market Size (US$ Billion), 2016-2020

Figure 7-10: US – Herceptin Market by Product (%), 2019

Figure 7-11: US – Expected Herceptin Market by Product (%), 2026

Figure 7-12: US – Kanjinti Market Size (US$ Million), 2019 and 2020

Figure 7-13: Kanjinti – Market Size by Region (%), 2020

Figure 7-14: US – Kanjinti Market Size (US$ Million), 2021-2026

Figure 7-15: US – Herceptin Biosimilar Market Size (US$ Million), 2020-2026

Figure 7-16: Global – Avastin Market Size (US$ Billion), 2016 - 2019

Figure 7-17: Avastin – Market Size by Region (%), 2019

Figure 7-18: US – Mvasi Market Size (US$ Million), 2019 and 2020

Figure 7-19: US – Mvasi Market Size (US$ Million), 2021-2026

Figure 7-20: Zirabev – Market Size by Region (%), 2020

Figure 7-21: US – Zirabev Market Size (US$ Million), 2020-2026

Figure 7-22: US – Avastin Biosimilar Market Size (US$ Million), 2020-2026

Figure 8-1: US – Erbitux Market Size (US$ Million), 2017-2019

Figure 8-2: US – Erbitux Market Size (US$ Million), 2021-2026

Figure 8-3: US – Erbitux Biosimilar Sales Opportunity by 5% of Total Cetuximab Market (US$ Million), 2021-2026

Figure 8-4: US – Erbitux Biosimilar Sales Opportunity by 10% of Total Cetuximab Market (US$ Million), 2021-2026

Figure 8-5: US – Erbitux Biosimilar Sales Opportunity by 15% of Total Cetuximab Market (US$ Million), 2021-2026

Figure 8-6: US – Erbitux Biosimilar Sales Opportunity by 20% of Total Cetuximab Market (US$ Million), 2021-2026

Figure 8-7: US – Erbitux Biosimilar Sales Opportunity by 25% of Total Cetuximab Market (US$ Million), 2021-2026

Figure 8-8: US – Vectibix Market Size (US$ Million), 2018-2020

Figure 8-9: US – Vectibix Market Size (US$ Million), 2021-2026

Figure 8-10: US – Vectibix Biosimilar Sales Opportunity by 5% of Total Panitumumab Market (US$ Million), 2021-2026

Figure 8-11: US – Vectibix Biosimilar Sales Opportunity by 10% of Total Panitumumab Market (US$ Million), 2021-2026

Figure 8-12: US – Vectibix Biosimilar Sales Opportunity by 15% of Total Panitumumab Market (US$ Million), 2021-2026

Figure 8-13: US – Vectibix Biosimilar Sales Opportunity by 20% of Total Panitumumab Market (US$ Million), 2021-2026

Figure 8-14: US – Vectibix Biosimilar Sales Opportunity by 25% of Total Panitumumab Market (US$ Million), 2021-2026

Figure 8-15: US – Yervoy Market Size (US$ Million), 2017-2020

Figure 8-16: US – Yervoy Market Size (US$ Million), 2021-2026

Figure 8-17: US – Yervoy Biosimilar Sales Opportunity by 5% of Total Ipilimumab Market (US$ Million), 2024-2026

Figure 8-18: US – Yervoy Biosimilar Sales Opportunity by 10% of Total Ipilimumab Market (US$ Million), 2024-2026

Figure 8-19: US – Yervoy Biosimilar Sales Opportunity by 15% of Total Ipilimumab Market (US$ Million), 2024-2026

Figure 8-20: US – Yervoy Biosimilar Sales Opportunity by 20% of Total Ipilimumab Market (US$ Million), 2024-2026

Figure 8-21: US – Yervoy Biosimilar Sales Opportunity by 25% of Total Ipilimumab Market (US$ Million), 2024-2026

Figure 8-22: US - Trodelvy Quarterly Sales Value (US$ Million), Q2 – Q4, 2020

Figure 8-23: US – Trodelvy Market Size (US$ Million), 2021-2026

Figure 8-24: US – Trodelvy Biosimilar Sales Opportunity by 5% of Total Sacituzumab Govitecan Market (US$ Million), 2024-2026

Figure 8-25: US – Trodelvy Biosimilar Sales Opportunity by 10% of Total Sacituzumab Govitecan Market (US$ Million), 2024-2026

Figure 8-26: US – Trodelvy Biosimilar Sales Opportunity by 15% of Total Sacituzumab Govitecan Market (US$ Million), 2024-2026

Figure 8-27: US – Trodelvy Biosimilar Sales Opportunity by 20% of Total Sacituzumab Govitecan Market (US$ Million), 2024-2026

Figure 8-28: US – Trodelvy Biosimilar Sales Opportunity by 25% of Total Sacituzumab Govitecan Market (US$ Million), 2024-2026

Figure 8-29: US – Perjeta Market Size (US$/CHF Million), 2018-2020

Figure 8-30: US – Perjeta Market Size (US$ Million), 2021-2026

Figure 8-31: US – Perjeta Biosimilar Sales Opportunity by 5% of Total Pertuzumab Market (US$ Million)

Figure 8-32: US – Perjeta Biosimilar Sales Opportunity by 10% of Total Pertuzumab Market (US$ Million)

Figure 8-33: US – Perjeta Biosimilar Sales Opportunity by 15% of Total Pertuzumab Market (US$ Million)

Figure 8-34: US – Perjeta Biosimilar Sales Opportunity by 20% of Total Pertuzumab Market (US$ Million)

Figure 8-35: US – Perjeta Biosimilar Sales Opportunity by 25% of Total Pertuzumab Market (US$ Million)

Figure 8-36: US - Gazyva Market Size (US$/CHF Million), 2017-2020

Figure 8-37: US – Gazyva Market Size (US$ Million), 2021-2026

Figure 8-38: US – Gazyva Biosimilar Sales Opportunity by 5% of Total Obinutuzumab Market (US$ Million)

Figure 8-39: US – Gazyva Biosimilar Sales Opportunity by 10% of Total Obinutuzumab Market (US$ Million)

Figure 8-40: US – Gazyva Biosimilar Sales Opportunity by 15% of Total Obinutuzumab Market (US$ Million)

Figure 8-41: US – Gazyva Biosimilar Sales Opportunity by 20% of Total Obinutuzumab Market (US$ Million)

Figure 8-42: US – Gazyva Biosimilar Sales Opportunity by 25% of Total Obinutuzumab Market (US$ Million)

Figure 8-43: US – Darzalex Market Size (US$ Million), 2018-2020

Figure 8-44: US – Darzalex Market Size (US$ Million), 2021-2026

Figure 8-45: US – Darzalex Biosimilar Sales Opportunity by 5% of Total Daratumumab Market (US$ Million)

Figure 8-46: US – Darzalex Biosimilar Sales Opportunity by 10% of Total Daratumumab Market (US$ Million)

Figure 8-47: US – Darzalex Biosimilar Sales Opportunity by 15% of Total Daratumumab Market (US$ Million)

Figure 8-48: US – Darzalex Biosimilar Sales Opportunity by 20% of Total Daratumumab Market (US$ Million)

Figure 8-49: US – Darzalex Biosimilar Sales Opportunity by 25% of Total Daratumumab Market (US$ Million)

Figure 8-50: US – Xgeva Market Size (US$ Million), 2018-2020

Figure 8-51: US – Xgeva Market Size (US$ Million), 2021-2026

Figure 8-52: US – Xgeva Biosimilar Sales Opportunity by 5% of Total Denosumab Market (US$ Million)

Figure 8-53: US – Xgeva Biosimilar Sales Opportunity by 10% of Total Denosumab Market (US$ Million)

Figure 8-54: US – Xgeva Biosimilar Sales Opportunity by 15% of Total Denosumab Market (US$ Million)

Figure 8-55: US – Xgeva Biosimilar Sales Opportunity by 20% of Total Denosumab Market (US$ Million)

Figure 8-56: US – Xgeva Biosimilar Sales Opportunity by 25% of Total Denosumab Market (US$ Million)

Figure 8-57: US – Cyramza Market Size (US$ Million), 2017-2020

Figure 8-58: US – Cyramza Market Size (US$ Million), 2021-2026

Figure 8-59: US – Cyramza Biosimilar Sales Opportunity by 5% of Total Ramucirumab Market (US$ Million)

Figure 8-60: US – Cyramza Biosimilar Sales Opportunity by 10% of Total Ramucirumab Market (US$ Million)

Figure 8-61: US – Cyramza Biosimilar Sales Opportunity by 15% of Total Ramucirumab Market (US$ Million)

Figure 8-62: US – Cyramza Biosimilar Sales Opportunity by 20% of Total Ramucirumab Market (US$ Million)

Figure 8-63: US – Cyramza Biosimilar Sales Opportunity by 25% of Total Ramucirumab Market (US$ Million)

Figure 8-64: US – Kadcyla Market Size (US$/CHF Million), 2018-2020

Figure 8-65: US – Kadcyla Market Size (US$ Million), 2021-2026

Figure 8-66: US – Kadcyla Biosimilar Sales Opportunity by 5% of Total Trastuzumab Emtansine Market (US$ Million)

Figure 8-67: US – Kadcyla Biosimilar Sales Opportunity by 10% of Total Trastuzumab Emtansine Market (US$ Million)

Figure 8-68: US – Kadcyla Biosimilar Sales Opportunity by 15% of Total Trastuzumab Emtansine Market (US$ Million)

Figure 8-69: US – Kadcyla Biosimilar Sales Opportunity by 20% of Total Trastuzumab Emtansine Market (US$ Million)

Figure 8-70: US – Kadcyla Biosimilar Sales Opportunity by 25% of Total Trastuzumab Emtansine Market (US$ Million)

Figure 8-71: US – Opdivo Market Size (US$ Million), 2017-2020

Figure 8-72: US – Opdivo Market Size (US$ Million), 2021-2026

Figure 8-73: US – Opdivo Biosimilar Sales Opportunity by 5% of Total Nivolumab Market (US$ Million)

Figure 8-74: US – Opdivo Biosimilar Sales Opportunity by 10% of Total Nivolumab Market (US$ Million)

Figure 8-75: US – Opdivo Biosimilar Sales Opportunity by 15% of Total Nivolumab Market (US$ Million)

Figure 8-76: US – Opdivo Biosimilar Sales Opportunity by 20% of Total Nivolumab Market (US$ Million)

Figure 8-77: US – Opdivo Biosimilar Sales Opportunity by 25% of Total Nivolumab Market (US$ Million)

Figure 8-78: US – Tagraxousp Market Size (US$ Million), 2019 and 2020

Figure 8-79: US – Tagraxousp Market Size (US$ Million), 2021-2026

Figure 8-80: US – Tagraxousp Biosimilar Sales Opportunity by 5% of Total Elzonris Market (US$ Million)

Figure 8-81: US – Tagraxousp Biosimilar Sales Opportunity by 10% of Total Elzonris Market (US$ Million)

Figure 8-82: US – Tagraxousp Biosimilar Sales Opportunity by 15% of Total Elzonris Market (US$ Million)

Figure 8-83: US – Tagraxousp Biosimilar Sales Opportunity by 20% of Total Elzonris Market (US$ Million)

Figure 8-84: US – Tagraxousp Biosimilar Sales Opportunity by 25% of Total Elzonris Market (US$ Million)

Figure 8-85: US – Tecentriq Market Size (US$/CHF Million), 2018-2020

Figure 8-86: US – Tecentriq Market Size (US$ Million), 2021-2026

Figure 8-87: US – Tecentriq Biosimilar Sales Opportunity by 5% of Total Atezolizumab Emtansine Market (US$ Million)

Figure 8-88: US – Tecentriq Biosimilar Sales Opportunity by 10% of Total Atezolizumab Emtansine Market (US$ Million)

Figure 8-89: US – Tecentriq Biosimilar Sales Opportunity by 15% of Total Atezolizumab Emtansine Market (US$ Million)

Figure 8-90: US – Tecentriq Biosimilar Sales Opportunity by 20% of Total Atezolizumab Emtansine Market (US$ Million)

Figure 8-91: US – Tecentriq Biosimilar Sales Opportunity by 25% of Total Atezolizumab Emtansine Market (US$ Million)

Figure 8-92: US – Keytruda Market Size (US$ Million), 2018-2020

Figure 8-93: US – Keytruda Market Size (US$ Billion), 2021-2026

Figure 8-94: US – Keytruda Biosimilar Sales Opportunity by 5% of Total Pembrolizumab Emtansine Market (US$ Million)

Figure 8-95: US – Keytruda Biosimilar Sales Opportunity by 10% of Total Pembrolizumab Emtansine Market (US$ Million)

Figure 8-96: US – Keytruda Biosimilar Sales Opportunity by 15% of Total Pembrolizumab Emtansine Market (US$ Million)

Figure 8-97: US – Keytruda Biosimilar Sales Opportunity by 20% of Total Pembrolizumab Emtansine Market (US$ Million)

Figure 8-98: US – Keytruda Biosimilar Sales Opportunity by 25% of Total Pembrolizumab Emtansine Market (US$ Million)

Figure 8-99: US – Keytruda Market Size (US$ Million), 2018-2020

Figure 8-100: US – Imfinzi Market Size (US$ Million), 2021-2026

Figure 8-101: US – Imfinzi Biosimilar Sales Opportunity by 5% of Total Durvalumab Emtansine Market (US$ Million)

Figure 8-102: US – Imfinzi Biosimilar Sales Opportunity by 10% of Total Durvalumab Emtansine Market (US$ Million)

Figure 8-103: US – Imfinzi Biosimilar Sales Opportunity by 15% of Total Durvalumab Emtansine Market (US$ Million)

Figure 8-104: US – Imfinzi Biosimilar Sales Opportunity by 20% of Total Durvalumab Emtansine Market (US$ Million)

Figure 8-105: US – Imfinzi Biosimilar Sales Opportunity by 25% of Total Durvalumab Emtansine Market (US$ Million)

Figure 11-1: US - New Cancer Cases by Region (Millions), 2020 and 2040

Figure 11-2: Approved Biosimilars in US and Europe

Figure 11-3: Europe – Biosimilar Market Size (US$ Billion), 2017-2020

Figure 11-4: Europe – Expected Biosimilar Market Size (US$ Billion), 2021-2026

Figure 11-5: Europe – Oncology Biosimilar Market Size (US$ Billion), 2017 - 2020

Figure 11-6: Japan – Emerging Cancer Cases and Deaths (Million), 2020 and 2040

Figure 11-7: Approved Biosimilars in US and Japan

Figure 11-8: First Biosimilar Approval Year by Region

Figure 11-9: Oncology Biosimilar Approved by Region

Figure 11-10: Japan – Cancer Biosimilar Market Size (US$ Million), 2018-2020

Figure 11-11: Japan – Expected Oncology Biosimilar Market Size (US$ Billion), 2021-2026

Figure 11-12: India – New Emerging Cases and Death by Cancer (Million), 2020 and 2040

Figure 11-13: Approved Biosimilars in India and US

Figure 11-14: India – Oncology Biosimilar Market Size (US$ Million), 2016-2019

Figure 11-15: India – Rituximab Biosimilar Price by Brand (USD/INR)

Figure 11-16: India – Pipeline of Biosimilars by Stage of Development

Figure 11-17: India – Pipeline of Biosimilars by Stage of Development (%)

Figure 11-18: India - Cancer Biosimilar Market Size (US$ Million), 2020-2026

Figure 11-19: China – New Cancer Cases and Associated Deaths (Million), 2020 and 2040

Figure 11-20: China – Biological Drugs Market Size (US$/Yuan Billion), 2019-2026

Figure 11-21: First Biosimilar Approval Year by Region

Figure 11-22: Total Biosimilar Approved by Region

Figure 11-23: China – Biosimilar Market Size (US$ Billion), 2019-2026

Figure 11-24: South Korea – Cancer Incidences, 2020 and 2040

Figure 11-25: South Korea – Cancer Mortality, 2020 and 2040

Figure 11-26: South Korea – Biological Drug Market Size (US$ Billion), 2016-2021

Figure 11-27: First Biosimilar Approval Year by Region

Figure 11-28: Number of Approved Biosimilars by Region

Figure 11-29: Approved Oncology Biosimilars by Region

Figure 11-30: Approved Oncology Biosimilars by Product

Figure 12-1: US – Annual Savings from Generics (US$ Billion), 2015-2019

Figure 12-2: US – Cost Savings in 10 years by Type (US$ Billion)

Figure 12-3: US – Generic vs Biosimilar Drug Market Size (US$ Billion), 2019-2026

Figure 13-1: Zirabev – Potential Cost Savings per Cycle, Monthly and Annualy (US$)

Figure 13-2: US- New Cancer Cases, 2020 and 2040

Figure 13-3: US- Cancer Mortality, 2020 and 2040

Figure 13-4: Kanjinti – Total Treatment Cost and Reimbursement Cost (US$)

Figure 13-5: Kanjinti- In Pocket Cost and Out Pocket Cost (%)

Figure 13-6: US – Biosimilar Market Drivers

Figure 13-7: US – Biosimilar Market Barriers

Figure 13-8: Manufacturing Process of Biosimilars

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Payment Request

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Accept Terms & Conditions And Privacy Policy

US Cancer Biosimilar Market Opportunity, Drug Dosage, Price and Clinical Trials Insight 2026

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

"US Cancer Biosimilar Market Opportunity, Drug Dosage, Price and Clinical Trials Insight 2026" Report highlights:

US Cancer Biosimilar Market Opportunity: > US$ 15 Billion By 2026

Currently 29 Cancer Biosimilar Approved In US Market

Pricing and Dosage Insight On More Than 10 Cancer Biosimilar Commercially Available In US Market

Cancer Biosimilar In Clinical Trials: > 10 Biosimilars

Comprehensive Insight On Cancer Biosimilar Clinical Trials Insight By Company and Indication

Insight On 15 Potential Cancer Biosimilars Market Opportunity By Popular Drugs Patent Expiry: Erbitux, Vectibix, Yervoy, Trodelvy, Perjeta, Gazyva, Darzlex, Xgeva, Cyramza, Kadcyla, Opdivo, Tagraxofusp, Tecentriq, Keytruda, Imfinzi

Biosimiliars: A New Era in Cancer Therapeutics

1.1 Overview to Cancer Biosimilars

1.2 History of Biosimilars

Development of Biosimilars

Need of Cancer Biosimilars in US

US Comparative Price Analysis of Marketed Cancer Bosimilars

4.1 Avastin

4.2 Herceptin

4.3 Rituximab

US Reimbursement Scenario for Cancer Biosimilars

5.1 Current Scenario

5.2 Future Potential of Reimbursement Scenario

US Cancer Biosimilar Market Overview

6.1 Current Biosimilar Market Scenario

6.2 US Cancer Biosimilar Market

6.3 Off Going Patents: Biosimilar Opportunity Ahead

US Cancer Biosimilar Market by Product

7.1 Rituximab

7.2 Herceptin

7.3 Avastin

US Potential Cancer Biosimilars Market Oppotunity By Popular Drugs Patent Expiry

8.1 Erbitux Biosimilar

8.2 Vectibix Biosimilar

8.3 Yervoy Biosimilar

8.4 Trodelvy Biosimilar

8.5 Perjeta Biosimilar

8.6 Gazyva Biosimilar

8.7 Darzlex Biosimilar

8.8 Xgeva Biosimilar

8.9 Cyramza Biosimilar

8.10 Kadcyla Biosimilar

8.11 Opdivo Biosimilar

8.12 Tagraxofusp Biosimilar

8.13 Tecentriq Biosimilar

8.14 Keytruda Biosimilar

8.15 Imfinzi Biosimilar

US Biosimilar Clinical Pipeline By Company Indication and Phase

9.1 Preclinical

9.2 Phase-I

9.3 Phase-III

9.4 Preregistration

9.5 Registered

US Marketed Biosimilar Clinical Insight

US Cancer Biosimilar Market vs. Global Cancer Biosimilar Market

11.1 Europe Cancer Biosimilar Market

11.2 Japan Cancer Biosimilar Market

11.3 India Cancer Biosimilar Market

11.4 China Cancer Biosimilar Market

11.5 South Korea Cancer Biosimilar Market

US Biosimilar vs Generic Cancer Drug Market

US Cancer Biosimilar Market Dynamics

13.1 US Cancer Biosimilar Market Drivers

13.2 Barriers to US Biosimilar Market

US Cancer Biosimilar Future Outlook

Competitive Landscape

15.1 Amgen

15.2 AstraZencea

15.3 Biogen

15.4 Coherus Bioscience

15.5 Eli Lilly

15.6 F. Hoffmann-La Roche and Co.

15.7 Merck

15.8 Mylan Pharmaceuticals

15.9 Pfizer

15.10 Teva Pharmaceutical

Figure 1-1: List of Approved Cancer Biosimilars in US

Figure 2-1: Development Pathway for Biosimilar vs. Traditional

Figure 2-2: Development Process for Biosimilars

Figure 3-1: US – Spending on Cancer Care (US$ Billion), 2015-2030

Figure 4-1: Biosimilar Market Relationship

Figure 4-2: US – Avastin, Mvasi and Zirabev Approval Year